 |
|
|
| |
Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D
(AbT-450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
SJ Johnson1, JC Samp2, TR Juday2, SE Marx2, H Parisé1, S virabhak1, S Saab3
1Medicus Economics, Milton, 2Global Health Economics and Outcomes Research, Abbvie, Mettawa, 3Pfleger Liver Institute, Los Angeles, United States
|
| |
|
|
|
|
|
